Abstract
Objective
Patients with refractory status epilepticus (RSE) have failed treatment with benzodiazepines and ≥1 second-line intravenous (IV) anti-seizure medication (ASM). Guidelines recommend IV anesthesia when second-line ASMs have failed, but potential harms can outweigh benefits. Novel treatments are needed to stop and durably control RSE without escalation to IV anesthetics. Ganaxolone is an investigational neuroactive steroid in development for RSE treatment. This study’s objective was to determine the appropriate dosing for IV ganaxolone in RSE and obtain a preliminary assessment of ...
Seguir leyendo →JUN